Abstract
Background: Arterial hypertension is the largest single contributor to global mortality, and is poorly controlled in approximately 50% of patients despite lifestyle and pharmacologic interventions. Renal sympathetic hyperactivity is a key factor in the maintenance and progression of hypertension and randomized clinical trials have shown that catheter-based renal sympathetic denervation reduces blood pressure (BP) in patients with resistant hypertension. “Real world” data regarding the eficacy of this novel therapy are not available.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
